Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome.
Abstract
Atypical hemolytic uremic syndrome (aHUS) is caused by alternative complement pathway dysregulation, leading to systemic thrombotic microangiopathy (TMA) and severe end-organ damage. Based on 2 prospective studies in mostly adults and retrospective data in children, eculizumab, a terminal complement inhibitor, is approved for aHUS treatment. Here we prospectively evaluated efficacy and safety of weight-based dosing of eculizumab in eligible...
Paper Details
Title
Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome.
Published Date
Mar 1, 2016
Journal
Volume
89
Issue
3
Pages
701 - 711
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History